Last year, the race to be the first next-generation oral anti-viral hepatitis C drug culminated with Vertex Pharmaceuticals (NASDAQ: VRTX ) and Merck (NYSE: MRK ) getting their drugs approved a little over a week apart. Vertex’s Incivek went on to dominate the market.
But both drugs still require pegylated interferon, which has to be
injected and has some nasty side effects. The year 2012 has been a
banner year for drugmakers developing all-oral regimens that eliminate